Compare MLI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLI | MRNA |
|---|---|---|
| Founded | 1917 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 11.5B |
| IPO Year | N/A | 2018 |
| Metric | MLI | MRNA |
|---|---|---|
| Price | $133.91 | $47.58 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $32.75 |
| AVG Volume (30 Days) | 659.9K | ★ 13.7M |
| Earning Date | 02-03-2026 | 02-13-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 29.94 | N/A |
| EPS | ★ 6.68 | N/A |
| Revenue | ★ $4,139,698,000.00 | $2,232,000,000.00 |
| Revenue This Year | $12.24 | N/A |
| Revenue Next Year | $8.09 | $3.18 |
| P/E Ratio | $20.03 | ★ N/A |
| Revenue Growth | ★ 15.71 | N/A |
| 52 Week Low | $66.84 | $22.28 |
| 52 Week High | $135.08 | $55.20 |
| Indicator | MLI | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 75.88 | 69.65 |
| Support Level | $131.36 | $39.21 |
| Resistance Level | $135.08 | $55.20 |
| Average True Range (ATR) | 2.62 | 3.20 |
| MACD | 0.62 | 1.17 |
| Stochastic Oscillator | 92.07 | 66.58 |
Mueller Industries Inc makes copper, brass, aluminum, and plastic products. The company reports three business segments: piping systems, industrial metals, and climate. Piping systems, earning majority of the company's revenue, produces tubes, fittings, rods, valves, and other products and operates various firms world-wide. The industrial metals segment manufactures impacts and micro-gauge, brass rod and copper bar products, and brass value-added products. The climate segment produces items used to create temperature-control goods, including valves, twisted tubes, coaxial heat exchangers, and others. Numerous systems use the aforementioned products, including HVAC, water distribution, refrigeration, and automotive.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.